In this large population-based cohort study including 4753 adult patients with breast cancer, tamoxifen combined with a DOAC was not associated with a higher risk of major hemorrhage requiring an emergency department visit or hospitalization compared with the combination of an aromatase inhibitor and a DOAC. This evidence concerns the gene CYP19A1 and breast carcinoma.